HC Wainwright Has Pessimistic Outlook of Nkarta Q3 Earnings

Key Points

• HC Wainwright analysts have revised down Nkarta's Q3 2025 earnings per share estimate to ($0.31), lower than the previous expectation of ($0.26).
• Nkarta's last quarterly earnings report showed an actual EPS of ($0.31), which was better than the consensus estimate of ($0.37).
• Analyst ratings for Nkarta include one "hold," five "buy," and one "strong buy," with a consensus price target of $13.60.

Nkarta, Inc. (NASDAQ:NKTX - Free Report) - Investment analysts at HC Wainwright decreased their Q3 2025 EPS estimates for Nkarta in a research note issued to investors on Wednesday, August 13th. HC Wainwright analyst E. Bodnar now forecasts that the company will earn ($0.31) per share for the quarter, down from their prior estimate of ($0.26). The consensus estimate for Nkarta's current full-year earnings is ($1.70) per share. HC Wainwright also issued estimates for Nkarta's Q4 2025 earnings at ($0.32) EPS, FY2025 earnings at ($1.38) EPS, FY2026 earnings at ($1.63) EPS, FY2027 earnings at ($2.00) EPS, FY2028 earnings at ($1.37) EPS and FY2029 earnings at ($0.88) EPS.

Other analysts have also issued research reports about the company. Stifel Nicolaus lowered their target price on Nkarta from $14.00 to $12.00 and set a "buy" rating on the stock in a report on Thursday, August 14th. Wall Street Zen raised Nkarta from a "sell" rating to a "hold" rating in a report on Saturday. Mizuho lowered their target price on Nkarta from $16.00 to $14.00 and set an "outperform" rating on the stock in a report on Tuesday, June 10th. Needham & Company LLC reaffirmed a "buy" rating and issued a $10.00 target price on shares of Nkarta in a report on Wednesday, August 13th. Finally, William Blair reaffirmed a "market perform" rating on shares of Nkarta in a report on Thursday, May 15th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, Nkarta has a consensus rating of "Buy" and an average price target of $13.60.

Nkarta Stock Down 2.1%

NKTX stock traded down $0.05 during mid-day trading on Friday, reaching $2.30. 536,847 shares of the stock traded hands, compared to its average volume of 954,760. Nkarta has a 52 week low of $1.31 and a 52 week high of $6.63. The business has a 50-day moving average of $1.94 and a two-hundred day moving average of $1.88. The firm has a market capitalization of $163.37 million, a PE ratio of -1.55 and a beta of 0.72.

Nkarta (NASDAQ:NKTX - Get Free Report) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.37) by $0.06.

Hedge Funds Weigh In On Nkarta

Several hedge funds and other institutional investors have recently modified their holdings of NKTX. Jefferies Financial Group Inc. lifted its position in shares of Nkarta by 901.7% during the 4th quarter. Jefferies Financial Group Inc. now owns 2,504,219 shares of the company's stock worth $6,236,000 after buying an additional 2,254,219 shares during the period. Tang Capital Management LLC lifted its position in shares of Nkarta by 252.9% during the 4th quarter. Tang Capital Management LLC now owns 2,293,719 shares of the company's stock worth $5,711,000 after buying an additional 1,643,719 shares during the period. JPMorgan Chase & Co. lifted its position in shares of Nkarta by 138.7% during the 4th quarter. JPMorgan Chase & Co. now owns 2,537,922 shares of the company's stock worth $6,319,000 after buying an additional 1,474,560 shares during the period. Jane Street Group LLC lifted its position in shares of Nkarta by 118.7% during the 1st quarter. Jane Street Group LLC now owns 134,286 shares of the company's stock worth $247,000 after buying an additional 852,559 shares during the period. Finally, Monaco Asset Management SAM bought a new position in shares of Nkarta during the 1st quarter worth approximately $1,496,000. Institutional investors own 80.54% of the company's stock.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.